Product
Darovasertib
Aliases
IDE196, LXS196
2 clinical trials
2 indications
Indication
Uveal melanomaIndication
Ocular melanomaClinical trial
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaStatus: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-11-01